Biosimilars Research Pipeline

A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. Only minor differences in clinically inactive components are allowable in biosimilar products. Biosimilar innovative products are on the rise. The numbers of new drugs seeking approval are growing at a compounded rate of around 5% half early. Almost 1.5 times the number of biosimilars are expected to be in the market in 2017 compared to in the last 5 years.

  • Biotechnology medicinal products for different diseases/disorders
  • Biosimilars for Autoimmune diseases
  • Biosimilars in Dermatological diseases
  • Biosimilar antibodies
  • Biopharmaceuticals development
  • Future of next generation biosimilars

Related Conference of Biosimilars Research Pipeline

June 06-07, 2018

International Conference on Pharmaceutical Research and Development

Philadelphia, Pennsylvania, USA
June 08-09, 2018

8th International Conference and Exhibition on GMP, GCP & Quality Control

Philadelphia, Pennsylvania, USA
June 08-09, 2018

7th International conference on Pharmaceutical Auditing

Philadelphia, Pennsylvania, USA
June 27-28, 2018

4th International Conference on Drug Discovery, Designing and Development

Vancouver, British Columbia, Canada
August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan

3rd International Conference on Generics Drugs and Biosimilars

November 15-17, 2018 | Frankfurt, Germany
October 18-19, 2018

18th World Pharma Congress

Warsaw, Poland
August 15-17, 2018

8th World Congress Spectroscopy and Analytical Techniques

Stockholm, Sweden
September 18-19, 2018

6th European Biopharma Congress

Amsterdam, Netherlands

Biosimilars Research Pipeline Conference Speakers

Recommended Sessions

Related Journals

Are you interested in